Physician profile
Harry Snapperman
NPI 1598850703
$2,727.22
in general payments reported to CMS, 2019-2025
28 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.42 · 2020: $31.12 · 2021: $51.24 · 2022: $376 · 2023: $624 · 2024: $786 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,120 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $484.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $390.06 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $330.85 | 2023-2025 | |
| Abbvie INC. | $241.92 | 2021-2025 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $159.25 | 2023-2024 | Veozah |
| Abbott Laboratories | $152.60 | 2019-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $98.16 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $93.47 | 2023-2025 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $89.34 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.57 | 2023-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $69.97 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $60.41 | 2023-2024 | Quviviq |
| Dexcom, INC. | $55.88 | 2023-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $46.55 | 2024 | Azstarys |
| Amgen INC. | $46.19 | 2023-2025 | Repatha, Otezla, Repatha |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $45.85 | 2025 | Fluad, Flucelvax |
| Corcept Therapeutics | $42.72 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $40.97 | 2019-2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Currax Pharmaceuticals LLC | $31.55 | 2022-2024 | Contrave |
| Exact Sciences Corporation | $28.90 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $25.78 | 2025 | |
| Optinose US, INC. | $23.30 | 2025 | |
| Phathom Pharmaceuticals, INC. | $21.81 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $16.90 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $14.49 | 2023 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $14.49 | 2025 | Qelbree |
| Radius Health, INC. | $14.30 | 2019 | |
| Amarin Pharma, INC. | $11.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Snapperman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.